Altamira Therapeutics (NASDAQ:CYTO) stock soared 44% in midday trading Monday after the biotech company announced a collaboration with Univercells for the potential development of mRNA vaccines using Altamira’s SemaPhore nanoparticle technology.
Under the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with SemaPhore nanoparticles. If the tests are successful, the companies intend to negotiate a commercial deal for the development and manufacture of nanoparticle-based mRNA vaccines using Univercells’ production platform, according to Altamira.
